CALCIMEDICA RSS Feed | Nachrichten - www.finanzen.net

CalciMedica stellte das Zahlenwerk zum vergangenen Quartal vor

Thu, 05 Mar 2026 06:35:06 +0100

CalciMedica hat am 03.03.2026 die Bücher zum am 31.12.2025 abgelaufenen Jahresviertel geöffnet.Das EPS wurde auf einen Verlust von 0,69 USD je Aktie beziffert. Im Vorjahresviertel waren -0,340 USD je Aktie erzielt ...

CalciMedica legte die Bilanz zum abgelaufenen Quartal vor

Fri, 14 Nov 2025 06:35:06 +0100

CalciMedica präsentierte in der am 12.11.2025 stattfindenden Finanzkonferenz das Zahlenwerk zum jüngsten Quartal, welches am 30.09.2025 endete.Das EPS wurde auf einen Verlust von 0,52 USD je Aktie beziffert. Im ...

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Wed, 12 Nov 2025 13:01:00 +0100

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026

Positive ...

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

Wed, 12 Nov 2025 13:00:00 +0100

Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination ...

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Mon, 10 Nov 2025 13:00:00 +0100

Treatment with Auxora significantly reduced IL-17–related inflammation in both kidney and lung, significantly increased glomerular filtration rate (GFR), and decreased renal injury in a rat model ...

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

Tue, 14 Oct 2025 13:00:00 +0200

AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials